Literature DB >> 30763151

Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.

Zhenning Yu1, Viswanathan Ramakrishnan2, Caitlyn Meinzer3.   

Abstract

Multi-arm multi-stage designs, in which multiple active treatments are compared to a control and accumulated information from interim data are used to add or remove arms from the trial, may reduce development costs and shorten the drug development timeline. As such, this adaptive update is a natural complement to Bayesian methodology in which the prior clinical belief is sequentially updated using the observed probability of success. Simulation is often required for planning clinical trials to accommodate the complexity of the design and to optimize key design characteristics. This paper addresses two key limiting factors in simulations, namely the computational burden and the time needed to obtain results. We first introduce a generic process for simulating Bayesian multi-arm multi-stage designs with binary endpoints. Then, to address the computational burden and time, we optimize the method for calculating the posterior probability and posterior predictive probability of success.

Entities:  

Keywords:  Bayesian; clinical trial; multi-arm multi-stage design; simulation

Mesh:

Substances:

Year:  2019        PMID: 30763151      PMCID: PMC7751063          DOI: 10.1080/10543406.2019.1577682

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  13 in total

1.  Bayesian two-stage designs for phase II clinical trials.

Authors:  Say-Beng Tan; David Machin
Journal:  Stat Med       Date:  2002-07-30       Impact factor: 2.373

2.  Optimal design of multi-arm multi-stage trials.

Authors:  James M S Wason; Thomas Jaki
Journal:  Stat Med       Date:  2012-07-23       Impact factor: 2.373

3.  The what, why and how of Bayesian clinical trials monitoring.

Authors:  L S Freedman; D J Spiegelhalter; M K Parmar
Journal:  Stat Med       Date:  1994 Jul 15-30       Impact factor: 2.373

4.  A Bayesian inference of P(π1 > π2) for two proportions.

Authors:  Youhei Kawasaki; Etsuo Miyaoka
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

5.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

6.  The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.

Authors:  Benjamin R Saville; Jason T Connor; Gregory D Ayers; JoAnn Alvarez
Journal:  Clin Trials       Date:  2014-05-28       Impact factor: 2.486

Review 7.  Current status of neuroprotection for cerebral ischemia: synoptic overview.

Authors:  Myron D Ginsberg
Journal:  Stroke       Date:  2008-12-08       Impact factor: 7.914

8.  Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control.

Authors:  John Whitehead; Faye Cleary; Amanda Turner
Journal:  Stat Med       Date:  2015-03-12       Impact factor: 2.373

9.  More multiarm randomised trials of superiority are needed.

Authors:  Mahesh K B Parmar; James Carpenter; Matthew R Sydes
Journal:  Lancet       Date:  2014-07-26       Impact factor: 79.321

10.  Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.

Authors:  Louis Jacob; Maria Uvarova; Sandrine Boulet; Inva Begaj; Sylvie Chevret
Journal:  BMC Med Res Methodol       Date:  2016-06-02       Impact factor: 4.615

View more
  2 in total

1.  Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.

Authors:  Elja Arjas; Dario Gasbarra
Journal:  BMC Med Res Methodol       Date:  2022-02-20       Impact factor: 4.615

2.  Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19.

Authors:  Nigel Stallard; Lisa Hampson; Norbert Benda; Werner Brannath; Thomas Burnett; Tim Friede; Peter K Kimani; Franz Koenig; Johannes Krisam; Pavel Mozgunov; Martin Posch; James Wason; Gernot Wassmer; John Whitehead; S Faye Williamson; Sarah Zohar; Thomas Jaki
Journal:  Stat Biopharm Res       Date:  2020-07-29       Impact factor: 1.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.